Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale (Q22252358)

Europe PubMed Central

title

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale (English)

0 references

Anil Bagri

1

Anil

Bagri

1 reference

8 February 2023

Hosein Kouros-Mehr

series ordinal

2

author given names

Hosein

author last names

Kouros-Mehr

1 reference

8 February 2023

Kevin G. Leong

series ordinal

3

author given names

Kevin G

author last names

Leong

1 reference

8 February 2023

Greg D. Plowman

series ordinal

4

author given names

Greg D

author last names

Plowman

1 reference

Trends in Molecular Medicine

8 February 2023

language of work or name

English

0 references

publication date

March 2010

0 references

published in

1 reference

Surgical adjuvant chemotherapy of metastatic murine tumors

volume

16

0 references

issue

3

0 references

page(s)

122-132

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Development of an animal model to study the biology of recurrent colorectal cancer originating from mesenteric lymph system metastases

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Access of tumor-derived macromolecules and cells to the blood: an electron microscopical study of structural barriers in microvessel clusters in highly malignant primary prostate carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Critical determinants of metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Different metastatic modes of malignant melanoma implanted in the ear of young and old mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Pathways mediating VEGF-independent tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Apc mice: models, modifiers and mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

The vascular niche and its basement membrane.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

VEGFR1-activity-independent metastasis formation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Tumorigenesis and the angiogenic switch

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

The metastatic niche: adapting the foreign soil

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Metastasis: from dissemination to organ-specific colonization

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Chemotherapy: Adding oxaliplatin to the equation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Treatment of primary breast cancer with chemotherapy and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Micrometastases or isolated tumor cells and the outcome of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Seeding and propagation of untransformed mouse mammary cells in the lung

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Neuropilins in tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Pericytes limit tumor cell metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Bevacizumab: current indications and future development for management of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

Colon cancer: update on adjuvant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLMED.2010.01.004

7 January 2021

10.1016/J.MOLMED.2010.01.004

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017